Victor Adepoju | Global Health | Excellence in Research

Dr. Victor Adepoju | Global Health | Excellence in Research

Director, Infectious diseases and Research at Jhpiego, Nigeria.

Dr. Victor Adepoju is a distinguished public health physician, researcher, and strategic information expert with over 14 years of experience managing large-scale global health programs across various income settings. As a Portfolio Director at Jhpiego, an affiliate of Johns Hopkins University, he leads multi-million-dollar projects in infectious diseases, maternal health, and immunization. With expertise in TB, HIV, viral hepatitis, and health systems strengthening, he has over 70 peer-reviewed publications and has contributed to WHO guidelines. Fluent in English and Yoruba, he is a global health leader driving universal health coverage and healthcare innovation.

Professional Profile:

Google Scholar

Education & Experience πŸŽ“πŸ’Ό

  • MBChB (Bachelor of Medicine & Surgery) – Obafemi Awolowo University πŸ₯
  • MSc (International Management of Health Systems) – University of Liverpool 🌍
  • Master Certificate in Healthcare Leadership – Cornell University 🎯
  • PhD (Public Health) – Crown International University πŸ†
  • Portfolio Director, Jhpiego (Johns Hopkins University Affiliate) (2021–Present) 🌍
  • Over 14 years in global health, working with USAID, Global Fund, GAVI, and UNITAID πŸ’‘

Professional Development πŸ“ˆπŸ©Ί

Dr. Adepoju is a seasoned expert in global health implementation, policy, and research. He has designed and led health interventions for TB, HIV, maternal and child health, and neglected tropical diseases, securing over $100 million in funding. His work in operational research, health systems strengthening, and digital health innovations has shaped policies globally. With experience in capacity building, health financing, and universal health coverage, he has collaborated with Ministries of Health, civil society, and donors. A thought leader in market shaping, he drives equitable access to healthcare solutions for vulnerable populations worldwide.

Research Focus πŸ”¬πŸ“š

Dr. Adepoju’s research spans infectious diseases (HIV, TB, viral hepatitis, COVID-19, and mpox), neglected tropical diseases, and maternal, newborn, and child health (MNCH). His expertise extends to universal health coverage, health systems strengthening, and innovative diagnostics. He is a leader in market shaping, improving access to essential medicines and vaccines in low- and middle-income countries (LMICs). His work also includes health financing, strategic information, and public-private partnerships. His contributions to implementation science have shaped WHO policies and national health guidelines across multiple regions.

Awards & Honors πŸ…πŸŽ–

  • An Excellence in Global Health Leadership Award πŸŒπŸ†
  • USAID/Global Fund Project Recognition Award πŸ₯πŸ’‘
  • Jhpiego Outstanding Leadership Award πŸ…
  • Best Public Health Research Paper Award πŸ“–
  • UNITAID Health Innovation Award πŸ’‰
  • Certificate of Excellence in Health Systems Strengthening πŸ†
  • Recognition for Policy Contribution to WHO Guidelines πŸ“œ

Publication Top Notes

πŸ“„ Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 – The Lancet 402 (10397), 203-234 πŸ“… 2023 πŸ” Cited by: 1972

πŸ“„ Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories, 1990–2021 – The Lancet 403 (10440), 2133-2161 πŸ“… 2024 πŸ” Cited by: 566

πŸ“„ Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 – The Lancet 403 (10440), 2100-2132 πŸ“… 2024 πŸ” Cited by: 530

πŸ“„ Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic – The Lancet 403 (10440), 1989-2056 πŸ“… 2024 πŸ” Cited by: 321

πŸ“„ The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis – The Lancet Global Health 12 (2), e201-e216 πŸ“… 2024 πŸ” Cited by: 112

πŸ“„ Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 – The Lancet 403 (10440), 2057-2099 πŸ“… 2024 πŸ” Cited by: 97

πŸ“„ Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021 – The Lancet Infectious Diseases 24 (9), 974-1002 πŸ“… 2024 πŸ” Cited by: 60

πŸ“„ Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the Global Burden of Disease Study 2019 – EClinicalMedicine 64 πŸ“… 2023 πŸ” Cited by: 54

πŸ“„ Prevalence of rifampicin-resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos, Nigeria – African Health Sciences 18 (3), 472-478 πŸ“… 2018 πŸ” Cited by: 48

πŸ“„ Childhood tuberculosis in Nigeria: disease presentation and treatment outcomes – Health Services Insights 11, 1178632918757490 πŸ“… 2018 πŸ” Cited by: 40